Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 32771000
Santio NM, et al. (2020) PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins. Cell Commun Signal 18, 121 32771000
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S106-p - CAPZA1 (human)
Modsite: DHLRkEAsDPQPEEA SwissProt Entrez-Gene
Orthologous residues
CAPZA1 (human): S106‑p, CAPZA1 (mouse): S106‑p, CAPZA1 (rat): S106‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mass spectrometry (in vitro), mutation of modification site
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Pim1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Pim1 (human) pharmacological inhibitor of upstream enzyme, microscopy-colocalization, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD1208 decrease
SGI-1776 decrease

S126-p - CAPZA1 (human)
Modsite: SWREsCDsALRAYVk SwissProt Entrez-Gene
Orthologous residues
CAPZA1 (human): S126‑p, CAPZA1 (mouse): S126‑p, CAPZA1 (rat): S126‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mass spectrometry (in vitro), mutation of modification site
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Pim1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Pim1 (human) pharmacological inhibitor of upstream enzyme, microscopy-colocalization, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD1208 decrease
SGI-1776 decrease

T186-p - CAPZB (human)
Modsite: tNKsGsGtMNLGGsL SwissProt Entrez-Gene
Orthologous residues
CAPZB (human): T186‑p, CAPZB iso2 (human): T186‑p, CAPZB (mouse): T186‑p, CAPZB iso2 (mouse): T186‑p, CAPZB (rat): T186‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mass spectrometry (in vitro), mutation of modification site
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Pim1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Pim1 (human) pharmacological inhibitor of upstream enzyme, microscopy-colocalization, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD1208 decrease
SGI-1776 decrease

S192-p - CAPZB (human)
Modsite: GtMNLGGsLtRQMEk SwissProt Entrez-Gene
Orthologous residues
CAPZB (human): S192‑p, CAPZB iso2 (human): S192‑p, CAPZB (mouse): S192‑p, CAPZB iso2 (mouse): S192‑p, CAPZB (rat): S192‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mass spectrometry (in vitro), mutation of modification site
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Pim1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Pim1 (human) pharmacological inhibitor of upstream enzyme, microscopy-colocalization, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD1208 decrease
SGI-1776 decrease

S226-p - CAPZB (human)
Modsite: DMENkIRsTLNEIyF SwissProt Entrez-Gene
Orthologous residues
CAPZB (human): S226‑p, CAPZB iso2 (human): S226‑p, CAPZB (mouse): S226‑p, CAPZB iso2 (mouse): S226‑p, CAPZB (rat): S226‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mass spectrometry (in vitro), mutation of modification site
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Pim1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Pim1 (human) pharmacological inhibitor of upstream enzyme, microscopy-colocalization, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD1208 decrease
SGI-1776 decrease